Best of ASH & SABCS 2024, Seattle

Seattle, WA US
January 5, 2024 to January 6, 2024

The Best of ASH & SABCS 2024, Seattle, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients. 

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

Organizing Committee 

Course Director:

Binay Shah, MD, MHA Binaytara Foundation

Co-Chairs:

Andrew J. Cowan, MD - Fred Hutchinson Cancer Center, University of Washington

Fengting Yan, MD, PhD, FACP - Swedish Cancer Institute 

Organizing Commitee Members: 

Loan Retchless,  ARNP, MSN- Panacea Oncology

Venue Information 

If you are attending this meeting and need to reserve a hotel room, please reserve your room at the link below to take advantage of the discounted group rate of $149 per night plus applicable taxes and fees:

 https://www.hyatt.com/en-US/group-booking/SEAGH/G-BTA1

The deadline to reserve the hotel room is Friday, December 15, 2023.

Learning Objectives

  1. Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.    
  2. Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
  3. Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
  4. Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
  5. Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.

Global Oncology Project

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal.

Course summary
Available credit: 
  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.
Course opens: 
09/21/2023
Course expires: 
03/30/2024
Event starts: 
01/05/2024 - 5:00pm PST
Event ends: 
01/06/2024 - 4:35pm PST
Cost:
$150.00

DAY 1 - January 5th, 2024

All times are listed in Pacific Time (PT)

04:00 PM – 04:45 PM: Registration/Networking & Exhibits


04:45 PM – 05:00 PM: Opening remarks


05:00 PM – 06:30 PM: Session 1 – Case-based discussion

Moderator: David Aboulafia, MD

Case 1 – Bleeding disorder- Livia Hegerova, MD

Case 2 – Smoldering myeloma- Aaron Goodman, MD

Case 3 – ITP/TTP- Sandhya Panch, MD, MPH

Case 4 – Anemia- Kleber Fertrin, MD, PhD

Case 5 – Bone marrow failure- Sioban Keel, MD


06:30 PM – 07:15 PM: Networking/reception & Exhibits


DAY 2 - January 6th, 2024

07:00 AM – 07:55 AM: Breakfast & Exhibits


08:00 AM – 09:30 AM: Session 2 

Moderator: Rachel Salit, MD

08:00 AM – 08:25 AM: MDS/Acute Leukemia- Jacob Appelbaum, MD, PhD 

08:25 AM – 08:50 AM: Myeloproliferative neoplasms and CML- Vivian Oehler, MD

08:50 AM – 09:15 AM: Cellular therapy in hematologic malignancies – recent updates- Krish Patel, MD

09:15 AM – 09:30 AM: Q & A


09:30 AM – 10:00 AM:  Break & exhibits

Product Theater Sponsored by Novartis *Non CME Activity* in Discovery Room

Topic: Addressing the Needs of Patients Across the HR+/HER2- Landscape: The Role of KISQALI (Ribociclib)

Speaker: Karthik Kumaravel, Associate Director, Market Access Strategy – Breast and Women’s Cancer


10:00 AM – 11:45 AM: Session 3

Moderator: Andrew Cowan, MD

10:00 AM – 10:25 AM: Lymphoma- Mengyang Di, MD, PhD

10:25 AM – 10:50 AM: Chronic lymphocytic leukemia- Mazyar Shadman, MD, MPH

10:50 AM – 11:15 AM: Multiple myeloma- Rahul Banerjee, MD, FACP

11:15 AM – 11:45 AM: Q & A


11:45 AM - 12:45 PM: Lunch & exhibits

Product Theater Sponsored by AstraZeneca *Non CME Activity* in Discovery Room

Topic: TRUQAP + fulvestrant: A Novel 2L Treatment Option for HR+/HER2- aBC or mBC With PIK3CA/AKT1/PTEN Alterations

Speaker: Dr. Lee Schwartzberg


12:45 PM - 02:30 PM: Session 4

Moderator: Tanya Wahl, MD

12:45 PM - 01:10 PM: Hormone receptor positive breast cancer- Hannah Linden, MD, FACP

01:10 PM - 01:35 PM: HER2 positive breast cancer- William Gwin III, MD

01:35 PM - 02:00 PM: Triple negative and HER2 low breast cancer- Sara Hurvitz, MD, FACP

02:00 PM – 02:30 PM: Q & A


02:30 PM – 02:45 PM: Break & exhibits


02:45 PM – 04:30 PM: Session 5

Moderator: Jennifer Specht, MD

02:45 PM – 03:10 PM: Radiotherapy – best breast practice- Li-Ming Christine Fang, MD

03:10 PM – 03:35 PM: Updates in surgical approach – best breast practice- Meghan Flanagan, MD, MPH

03:35 PM – 03:45 PM: Q & A

03: 45 PM- 04:00 PM: Arthracycline debate: To give or not to give- Jennifer Specht, MD

04:00 PM – 04:30 PM: Case-based discussion

Case 1 – DCIS- Lynn Symonds, MD

Case 2 – Inflammatory breast cancer- Peter Jiang, MD, PhD

Case 3 – Early Stage breast cancer- Danielle File, MD


04:30 PM – 04:35 PM: Adjourn

Grand Hyatt Seattle
721 Pine St
Seattle, WA 98101
United States

If you are attending this meeting and need to reserve a hotel room, please reserve your room at the link below to take advantage of the discounted group rate of $149 per night plus applicable taxes and fees:

 https://www.hyatt.com/en-US/group-booking/SEAGH/G-BTA1

The deadline to reserve the hotel room is Friday, December 15, 2023.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Andrew Cowan, MD

has a financial relationship (Independent contractor) with Abbvie;.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Jacob Appelbaum, MD/PhD

has no relevant financial relationships to disclose at this time.

Rahul Banerjee, MD, FACP

has a financial relationship (Grant Or Contract) with i3 Health;.
has a financial relationship (Independent contractor) with Clearview Healthcare Partners;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Grant Or Contract) with Clinical Care Options;.
has a financial relationship (Independent contractor) with Guidepoint Global;.
has a financial relationship (Grant Or Contract) with Pack Health;.
has a financial relationship (Grant Or Contract) with Curio Science;.
has a financial relationship (Independent contractor) with Sanofi Pasteur;.
has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Independent contractor) with SparkCures;.
has a financial relationship (Independent contractor) with Genentech/Roche;.

Mengyang Di, MD, PhD

has no relevant financial relationships to disclose at this time.

Li-Ming Fang, M.D.

has no relevant financial relationships to disclose at this time.

Meghan Flanagan, MD, MPH, FACS

has a financial relationship (Independent contractor) with Integro Theranostics;.

William Gwin

has no relevant financial relationships to disclose at this time.

Sara Hurvitz, MD

has a financial relationship (Grant Or Contract) with Dantari, LOXO;.
has a financial relationship (Grant Or Contract) with Phoenix Molecular Designs, Ltd., Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, Zymeworks;.
has a financial relationship (Grant Or Contract) with Arvinas, Astra Zeneca, Bayer, Celcuity, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, Greenwich Life Sciences Inc, GSK, Immunomedics, Eli Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer;.
has a financial relationship (Independent contractor) with Onclive, Curio;.

Hannah Linden, MD FACP

has a financial relationship (Grant Or Contract) with Veru Pharmaceuticals;.
has a financial relationship (Professional Services) with Gillead ;.
has a financial relationship (Grant Or Contract) with Tolmar;.
has a financial relationship (Grant Or Contract) with GE Healthcare ;.
has a financial relationship (Grant Or Contract) with Sanofi;.

Vivian Oehler

has a financial relationship (Other) with Novartis;.
has a financial relationship (Grant Or Contract) with Pfizer, Inc;.

Krish Patel, MD

has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Xencor;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
Case Presenter(s)

Kleber Fertrin, MD, PhD

has a financial relationship (Other) with Bluebird bio;.
has a financial relationship (Other) with Sanofi ;.
has a financial relationship (Grant Or Contract) with Agios Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Pfizer;.

Danielle File, MD

has no relevant financial relationships to disclose at this time.

Aaron Goodman, MD

has a financial relationship (Professional Services) with Seattle Genetics;.

Livia Hegerova

has a financial relationship (Grant Or Contract) with Rigel;.
has a financial relationship (Grant Or Contract) with Agios;.
has a financial relationship (Grant Or Contract) with Sanofi;.

Peter Jiang

has no relevant financial relationships to disclose at this time.

sioban keel, Siobán Keel, MD. Associate Professor of Medicine, University of Washington. Robert & Phyllis Henigson Endowed Chair, Medical Director of Fred Hutchinson Cancer Center Hematology Malignancy Genetics Clinic, Medical Director of The University of Washingto

has no relevant financial relationships to disclose at this time.

Sandhya Panch, MD MPH

has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Financial Support) with Sobi;.

Jennifer Specht, MD

has a financial relationship (Grant Or Contract) with Cascadian Therapeutics ;.
has a financial relationship (Professional Services) with Sensei Biotherapeutics;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Celcuity;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Necktar;.
has a financial relationship (Professional Services) with GE Healthcare;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Abbvie ;.
has a financial relationship (Other) with A2 Biotherapeutics ;.
has a financial relationship (Professional Services) with Volastra Therapeutics;.
has a financial relationship (Grant Or Contract) with Xencor;.

Lynn Symonds

has no relevant financial relationships to disclose at this time.
Moderator(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Andrew Cowan, MD

has a financial relationship (Independent contractor) with Abbvie;.

Rachel Salit, MD

has a financial relationship (Grant Or Contract) with Incyte Corporation;.

Tanya Wahl, Medical Oncologist, Medical Director Providence Swedish Cancer Institute Issaquah

has no relevant financial relationships to disclose at this time.
Planning committee(s)

LOAN RETCHLESS

has no relevant financial relationships to disclose at this time.

Available Credit

  • 8.25 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.25 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.25 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.